Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rocatinlimab in Adolescent Subjects With Moderate-to-severe Atopic Dermatitis
NCT05704738Phase 3Completed
- Sponsor
- Amgen
- Start
- Apr 2023
- Primary completion
- Feb 2025
- Modality
- Monoclonal Antibodies
- Countries
- 22
01
Overview
A Phase 3 trial of rocatinlimab in atopic dermatitis (AD), sponsored by Amgen. Started Apr 2023; status: completed.
02
Drugs
rocatinlimab
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT05704738.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05704738.